Skip to main content
SLS logo

SLS · SELLAS Life Sciences Group, Inc.

Track SLS — free
$13.86 +0.16 (+1.17%) At close · Sep 4
Market Cap
$2.80B
Shares
201.95M

Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.

Fails to Deliver History

Settlement Date Quantity Price Value
2026-08-14 44,054 $12.36 $544,507
2026-08-13 1,175 $11.77 $13,830
2026-08-12 232,228 $11.05 $2,566,119
2026-08-10 72,889 $12.01 $875,397
2026-08-06 474,248 $11.86 $5,624,581
2026-08-05 61,768 $11.81 $729,480
2026-08-04 16,052 $11.22 $180,103
2026-08-03 8,976 $10.01 $89,850
2026-07-31 6,559 $10.29 $67,492
2026-07-30 3,666 $10.10 $37,027
2026-07-29 33,812 $10.09 $341,163
2026-07-28 93,890 $10.84 $1,017,768
2026-07-27 491,784 $11.32 $5,566,995
2026-07-24 121,438 $12.34 $1,498,545
2026-07-23 31,047 $12.08 $375,048
2026-07-22 100 $12.90 $1,290
2026-07-21 79,405 $12.48 $990,974
2026-07-20 203,582 $13.19 $2,685,247
2026-07-17 21 $11.75 $247
2026-07-16 128,980 $12.79 $1,649,654
2026-07-15 291,911 $13.39 $3,908,688
2026-07-14 11,800 $12.62 $148,916
2026-07-13 118 $12.76 $1,506
2026-07-10 149,932 $13.51 $2,025,581
2026-07-09 227,834 $13.76 $3,134,996
2026-07-08 221,883 $13.50 $2,995,421
2026-07-07 168,936 $13.94 $2,354,968
2026-07-06 114,487 $14.98 $1,715,015
2026-07-02 58,256 $13.27 $773,057
2026-07-01 388,075 $14.76 $5,727,987
2026-06-30 3,634 $15.45 $56,145
2026-06-29 394,933 $12.39 $4,893,220
2026-06-26 229,096 $10.53 $2,412,381
2026-06-25 436,825 $9.17 $4,005,685
2026-06-24 1,063,738 $9.07 $9,648,104
2026-06-23 810,228 $8.53 $6,911,245
2026-06-22 1,920,359 $8.05 $15,458,890
2026-06-18 94,929 $7.76 $736,649
2026-06-17 35,302 $7.53 $265,824
2026-06-16 221,763 $7.73 $1,714,228
2026-06-15 52,019 $7.83 $407,309
2026-06-12 216,790 $7.75 $1,680,123
2026-06-11 7,816 $7.15 $55,884
2026-06-10 6,338 $7.68 $48,676
2026-06-09 209 $7.98 $1,668
2026-06-08 174,013 $8.23 $1,432,127
Showing 1–46 of 46 settlements
Key facts CIK 1390478 CUSIP 81642T209 13F (30d) 121 filings 121 filers Visit website Investor relations